ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note released on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for ORIC Pharmaceuticals’ FY2024 earnings at ($1.82) EPS. Several other research analysts have also commented on the company. Wedbush reaffirmed an outperform rating and set a […]
More Stories
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. Announces Monthly Dividend of $0.04 (NYSE:DCF)
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. (NYSE:DCF – Get Free Report) declared a monthly dividend...
First Trust Alternative Absolute Return Strategy ETF (FAAR) to Issue Quarterly Dividend of $0.20 on September 30th
First Trust Alternative Absolute Return Strategy ETF (NASDAQ:FAAR – Get Free Report) declared a quarterly dividend on Wednesday, September 25th,...
First Trust Capital Strength ETF (FTCS) To Go Ex-Dividend on September 26th
First Trust Capital Strength ETF (NASDAQ:FTCS – Get Free Report) announced a quarterly dividend on Wednesday, September 25th, NASDAQ reports....
AGM Group Holdings Inc. (NASDAQ:AGMH) Short Interest Update
AGM Group Holdings Inc. (NASDAQ:AGMH – Get Free Report) was the recipient of a large growth in short interest in...
Raffles Medical Group Ltd (OTCMKTS:RAFLF) Sees Significant Decrease in Short Interest
Raffles Medical Group Ltd (OTCMKTS:RAFLF – Get Free Report) was the recipient of a significant decrease in short interest in...
Short Interest in Legrand SA (OTCMKTS:LGRDY) Decreases By 90.6%
Legrand SA (OTCMKTS:LGRDY – Get Free Report) was the target of a large decline in short interest in September. As...